PURE Bioscience, Inc. (PURE)

PURE Bioscience Cash Flow Statement

Financials in millions USD. Fiscal year is August - July.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan 31, 2026	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Net Income	-2.16	-2.4	-3.35	-3.96	-3.49	-2.32
Depreciation & Amortization	0	0	0.15	0.12	0.21	0.17
Asset Writedown & Restructuring Costs	-	-	0.06	0.32	0.35	-
Stock-Based Compensation	0.16	0.15	0.21	0.32	0.57	0.84
Other Operating Activities	-	-	-	0.03	-0.16	0.15
Change in Accounts Receivable	-0.07	-0.18	-0.01	-0.08	0.17	0.72
Change in Inventory	-0.17	-0.09	0.03	0.06	0.08	0.07
Change in Accounts Payable	0.05	0.21	0.2	-0.04	-0.16	-0.78
Change in Other Net Operating Assets	0.37	0.29	0.18	-0.04	0.01	-0.02
Operating Cash Flow	-1.82	-2.02	-2.53	-3.28	-2.42	-1.17
Capital Expenditures	-	-	-	-0.03	-0.08	-0.52
Investing Cash Flow	-	-	-	-0.03	-0.08	-0.52
Long-Term Debt Issued	-	2	1.79	1.02	-	0.24
Total Debt Issued	1.82	2	1.79	1.02	-	0.24
Net Debt Issued (Repaid)	1.82	2	1.79	1.02	-	0.24
Issuance of Common Stock	-	-	-	-	3.5	-
Financing Cash Flow	1.82	2	1.79	1.02	3.5	0.24
Net Cash Flow	-0	-0.02	-0.75	-2.3	1	-1.45
Free Cash Flow	-1.82	-2.02	-2.53	-3.31	-2.5	-1.69
Free Cash Flow Margin	-75.78%	-91.51%	-128.94%	-176.40%	-134.86%	-42.98%
Free Cash Flow Per Share	-0.02	-0.02	-0.02	-0.03	-0.03	-0.02
Cash Income Tax Paid	0	0	0.01	0.01	0	0
Levered Free Cash Flow	-1.48	-1.51	-1.44	-1.95	-1.23	-0.82
Unlevered Free Cash Flow	-1.25	-1.32	-1.34	-1.94	-1.23	-0.81
Change in Working Capital	0.18	0.24	0.4	-0.11	0.1	-0.01

Updated Jan 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.